Friday 28 July 2017 The one stop source for free breaking news, expert analysis, and videos on AIM and LSE listed shares


Concepta - manufacturing deal signed in China: launch now very close

By Tom Winnifrith | Tuesday 27 September 2016


Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Concepta (CPT) has announced that it has signed a deal with a Chinese company, Huanzhong Biotech Limited ( HZ) to to assemble and package Concepta's 'My Lotus' fertility product. My Lotus already has regulatory clearance and so this paves the way for a launch very soon indeed.

Concepta states:

HZ Biotech will exclusively assemble and package Concepta produced components (including bulk tests and electronic meters), to produce Concepta's My Lotus product to specification for the Chinese market. HZ will utilise its manufacturing site and processes, adhering to locally applicable laws and Chinese regulatory requirements.

In addition to assembling the final My Lotus product, HZ Biotech will be the sole purchaser of Concepta's My Lotus product and help facilitate its launch to the Chinese market and include post-market surveillance. Concepta will also look to work with a network of distributors in China to help achieve maximum market penetration in China and will update the market on these developments in due course.

Concepta's MyLotus is the only consumer product which allows both quantitative and qualitative measurements of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems.

Ends.

Concepta states that an estimated 4 million women in China each year discover that they have unexplained infertility and that as such annual revenue potential for this target market is "expected to be worth" £250m per annum. Hmmmm, poor English. We think that means that the market potential is £250 million per annum.

But if My Lotus is as good as Concepta claims then it does not need much of a market share to justify a big premium to the current share price - at 18p the market cap is not a lot over £18 million.

And that is just China where we gather first sales will be made within days. 2016 will see a launch in the PRC. In 2017 we will see launches in the UK and Europe.

We expect more news on all fronts well before Christmas. You can see the potential and you can see that it is far from discounted. We are well up on the share tip (a 14p offer on this website) but on this news the stance is, at worst, a very strong hold. We continue to target 28p + to sell and to target that for before Christmas.

This article first appeared on the Nifty Fifty website which Lucian Miers runs with Tom Winnifrith & Steve Moore. To access the website ahead of the next share tip from Tom & Steve and ahead of a new shorting idea from Lucian GO HERE


Filed under:


Never miss a story.




This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.


More on CPT


Comments

Comments are turned off for this article.




Site by Everywhen